AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable VitiligoGlobeNewsWire • 12/15/21
AVITA Medical, Inc.'s (RCEL) CEO Mike Perry on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/09/21
AVITA Medical, Inc. (RCEL) Soars 8%: Is Further Upside Left in the Stock?Zacks Investment Research • 11/05/21
Regional Burn Conferences Feature 12 RECELL® System Data Presentations by Prominent Burn SurgeonsGlobeNewsWire • 10/28/21
AVITA Medical to Present at the 2021 Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/13/21
AVITA Medical, Inc.'s (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/27/21
U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric PatientsGlobeNewsWire • 06/10/21
AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of DirectorsGlobeNewsWire • 06/01/21
AVITA Medical's (RCEL) CEO Mike Perry on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21